Background: Colorectal cancer (CRC) is a malignant tumor. Recent studies have showed circular RNA (circRNA) participates in the development of CRC. The study was designed to reveal the role of circ_0011385 in CRC progression and underneath mechanism.Methods: The expression circ_0011385, microRNA-330-3p (miR-330-3p) and myosin VI (MYO6) mRNA were determined by quantitative real-time polymerase chain reaction. Protein expression was detected by Western blot assay. Cell proliferation was investigated by 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide (MTT), cell colony formation and flow cytometry assays. Cell apoptosis was demonstrated by flow cytometry analysis. Cell migration and invasion were evaluated by wound-healing assay and trans-well invasion assay, respectively. The binding sites between miR-330-3p and circ_0011385 or MYO6 were predicted by CircInteractome or starBase online databases, and identified by dual-luciferase reporter and RNA immunoprecipitation assays.Results: Circ_0011385 and MYO6 expression were dramatically upregulated, while miR-330-3p expression was downregulated in CRC tissues or cells compared with control groups. Circ_0011385 expression was associated with tumor size, tumor-node-metastasis stage (TNM) stage and lymph node metastasis of CRC patients. Circ_0011385 silencing or MYO6 absence repressed cell proliferation, migration and invasion, whereas induced cell apoptosis in CRC. Additionally, miR-330-3p inhibitor or MYO6 overexpression attenuated the repressive impacts of circ_0011385 silencing on CRC process. Circ_0011385 was asso-ciated with miR-330-3p, and miR-330-3p targeted MYO6. Circ_0011385 knockdown inactivated MEK1/2/ERK1/2 signaling pathway by miR-330-3p/MYO6 axis. Furthermore, circ_0011385 knockdown suppressed tumor growth in vivo.Conclusion: Circ_0011385 regulated CRC process by miR-330-3p/MYO6 axis through MEK1/2/ ERK1/2 signaling pathway, providing a novel therapeutic target for CRC.

Following the publication of the above paper, it was drawn to the Editor's attention by a concerned reader that certain of the tumour images in Fig. 3A and the immunohistochemistry data in Fig. 3C on p. 7, and colony formation assay data shown in Fig. 4F on p. 8 were strikingly similar to data that had already appeared in previous publications. Owing to the fact that the contentious data in the above article had already been published elsewhere, or were under consideration for publication, prior to its submission to International Journal of Molecular Medicine, the Editor has decided that this paper should be retracted from the Journal. After having been in contact with the authors, they accepted the decision to retract this paper. The Editor apologizes to the readership for any inconvenience caused. [International Journal of Molecular Medicine 47: 99, 2021; DOI: 10.3892/ijmm.2021.4932].

Background Neoadjuvant chemoradiotherapy (NCRT) is recommended as the treatment standard for locally advanced esophageal squamous cell carcinoma (ESCC). The use of immunotherapy in the neoadjuvant setting has gained attention. Multiple, clinical trials have explored the efficacy and safety of neoadjuvant immunochemotherapy (NICT). We evaluated the differences in clinicopathologic outcomes and the patterns of lymphatic spread among patients receiving neoadjuvant chemotherapy (NCT), NCRT, and NICT before esophagectomy for locally advanced ESCC. Methods A total of 702 patients with ESCC who completed transthoracic esophagectomy followed neoadjuvant therapy were included. Pathological characteristics, including pathologic complete response (pCR), tumor regression grade (TRG) score and patterns of lymphatic spread, were evaluated. Results Compared with the NCT group, the NCRT group and NICT group had an advantage in pathological response ( P < 0.05). The pCR rate was 8.1% in the NCT group, 29.9% in the NCRT group, and 23.6% in the NICT group. The TRG score ( P < 0.05) and pathologic T stage ( P < 0.05) in the NCT group were significantly higher. Compared with NICT, NCRT can significantly reduce the rate of lymph node metastasis rate in station 1R (0 vs. 3.4%, P < 0.05) and 2R (1.1% vs. 6.8%, P < 0.05). Subgroup analysis according to the tumor location distribution showed that NICT group had higher lymph node metastasis rate in station 2R (9.1%) in middle thoracic cases ( P < 0.05) and in station 18 (7.5%) ( P < 0.05) in lower thoracic cases. Conclusions NCRT or NICT followed by surgery may result in a promising pCR rate and show a better performance in therapeutic response of primary lesion. For patients with lymph node metastasis in station 1R and 2R, NCRT should be the optimal preoperative treatment strategy.

Objective To investigate the expression of pseudokinase Tribbles homology 3(TRIB3)and its clinical prognostic value in Siewert type Ⅱ adenocarcinoma of esophagogastric junction(AEG).Methods Western blot and immunohistochemical method were used to detect the expression of TRIB3 in R0 resected Siewert type Ⅱ AEG and its corresponding adjacent tissues,and analyze its rela-tionship with clinical parameters,survival and prognosis.Results Western blot analysis showed that the expression level of TRIB3 in Siewert type Ⅱ AEG tissues was significantly lower than that in the adjacent tissues(P<0.05).The immunohistochemical Results showed that the positive expression rate of TRIB3 in cancer tissues was significantly lower than that in adjacent tissues(P<0.01).The expression of TRIB3 was significantly correlated with the degree of differentiation,clinical TNM stage and lymph node metastasis(P<0.05),but not with age,gender and pathological morphology(P>0.05).Kaplan-Meier survival analysis showed that the long-term survival of patients with positive TRIB3 expression was significantly better than that of patients with negative TRIB3 expression(P<0.01).Univariate(HR =0.290,95%CI:0.110-0.761,P =0.012)and multivariate(HR =0.179,95%CI:0.051-0.630,P = 0.007)COX regression analysis showed that TRIB3 could be used as an independent prognostic factor for patients with Siewert type ⅡAEG(P<0.05).Conclusion TRIB3 may be involved in the occurrence and development of Siewert typeⅡ AEG.It is expected to be-come a new target for early diagnosis and treatment of AEG,and can be used as an important indicator for judging the prognosis of patients.

目的 探讨转录激活因子4(activating transcription factor 4,ATF4)的表达与Siewert Ⅱ型食管胃结合部腺癌(adenocarcinoma of esophagogastric junction,AEG)患者临床病理特征及预后的关系.方法 回顾性收集行R0 切除的 80 例Siewert Ⅱ型AEG患者的临床病理资料,采用免疫组化SP法检测Siewert Ⅱ型AEG及对应癌旁组织中ATF4 的表达情况,观察患者临床特征、生存情况,并通过Cox风险比例模型分析其与预后的关系.结果 ATF4 在Siewert Ⅱ型AEG中的阳性表达率为 28.8％(23/80),显著低于癌旁组织的 87.5％(70/80),差异有统计学意义(P＜0.001).此外,ATF4 的表达与AEG的分化程度、TNM分期及淋巴结转移均有明显的相关性(P＜0.05).80 例患者的中位随访时间为 120 个月(95％CI:108.542～131.458).Kaplan-Meier生存分析显示,ATF4 表达阳性的患者长期生存明显优于阴性的患者(P＜0.001).单因素分析显示TNM分期(HR=2.082,95％CI:1.065～4.070,P =0.032)和ATF4 的表达(HR =0.214,95％CI:0.096～0.480,P＜0.001)可能是患者总生存期的影响因素.进一步多因素分析结果显示ATF4(HR=0.156,95％CI:0.057～0.428,P＜0.001)可作为AEG患者的独立预后因子.结论 ATF4 可能在AEG的发生、发展过程中发挥重要作用,未来有望成为Siewert Ⅱ型AEG患者远期预后判断的新的生物标志物.

ImportanceThe optimal treatment for and potential benefit populations of synchronous oligometastatic esophageal squamous cell carcinoma (SOESCC) remain unclear.ObjectivesTo evaluate outcomes of concurrent chemoradiotherapy (CCRT) and to construct decision tree models for predicting the risk of progression and mortality in patients with SOESCC.Design, Setting, and ParticipantsThis prognostic study included 532 patients with SOESCC who were treated at 2 cancer centers in China from January 2012 to December 2018 and consisted of a development cohort (n = 381) and a validation cohort (n = 151). Data were analyzed from March 2019 to December 2021.ExposuresAll patients received chemotherapy alone or CCRT.Main Outcomes and MeasuresThe primary end points of the study were progression-free survival (PFS) and overall survival (OS), and the secondary end points were locoregional control and treatment-related toxic effects. Propensity score matching was performed to control potential confounding factors. Cox regression was used to screen important explanatory variables. Decision trees for optimally partitioning patients were established using recursive partitioning analysis and were then subjected to internal and independent external validation.ResultsAmong the 532 patients (median [range] age, 63 [32-82] years; 367 men [69.0%]), 292 patients received chemotherapy alone and 240 patients underwent CCRT. With a median (IQR) follow-up time of 37.0 (21.6-55.8) months, CCRT was associated with improved objective response rate (139 of 240 [57.9%] vs 123 of 292 [42.1%]; P < .001), median (IQR) PFS (9.7 [8.5-10.9] months vs 7.6 [6.6-8.6] months; P < .001), and median (IQR) OS (18.5 [16.1-20.9] months vs 15.2 [13.6-16.8] months; P < .001) compared with chemotherapy alone. Propensity score matching analysis verified the results. Cox multivariate analysis indicated that treatment modality (CCRT vs chemotherapy alone) was an independent prognostic factor related to PFS (hazard ratio, 0.69; 95% CI, 0.57-0.83; P < .001) and OS (hazard ratio, 0.75; 95% CI, 0.61-0.93; P = .008). The final decision trees divided patients with SOESCC into low-, intermediate-, and high-risk groups in both the internal and external validations, and the corresponding cumulative risk function curves had significant differences (all P < .001). Time-dependent maximum areas under receiver operating curves of decision trees for progression risk at 3 years and mortality risk at 5 years were 0.820 (95% CI, 0.693-0.948) and 0.894 (95% CI, 0.822-0.966), respectively. Calibration curves also demonstrated that the decision trees had favorable performance of risk stratification.Conclusions and RelevanceIn this study, CCRT vs chemotherapy alone as a first-line treatment for patients with SOESCC had superior survival. Patients with low risk had promising long-term survival based on the current treatment modality. The predictive information of the decision tree could provide accurate decision-making for the management of patients with SOESCC.

目的 探讨新辅助治疗对胸段食管鳞癌淋巴结转移模式及疗效的影响因素,为淋巴结清除范围和术后辅助治疗策略提供参考.方法 回顾性分析在武汉大学人民医院和郑州大学附属肿瘤医院2005-09-01-2015-09-01行食管癌根治术的2126例胸段食管鳞癌患者病例资料,按照第8版食管癌TNM分期系统重新分期.根据治疗方式不同分为单纯手术组、新辅助化疗+手术组和新辅助放化疗+手术组.使用倾向性得分匹配法平衡病例特征,纳入病例642例,其中单纯手术组和新辅助化疗+手术组各281例,新辅助放化疗+手术组80例.采用χ2检验或连续校正χ2检验或Fisher确切概率法分析淋巴结转移模式.病理完全缓解(pCR)定义为术后病理检查无肿瘤细胞残留,采用二分类Logistic回归分析pCR的独立影响因素.结果 642例胸段食管鳞癌患者淋巴结转移率为26.79％(172/642),淋巴结转移度为6.55％(753/11503).3组右喉返神经旁淋巴结(χ2=9.048,P=0.008)、左喉返神经旁淋巴结(χ2=9.153,P=0.010)、隆突下淋巴结(χ2=30.215,P<0.001)、胸下段食管旁淋巴结(χ2=8.566,P=0.012)和胃左动脉旁淋巴结(χ2=22.476,P<0.001)转移率差异有统计学意义.单纯手术组、新辅助化疗+手术组和新辅助放化疗+手术组的pCR率分别为0、12.46％(35/281)和31.25％(25/80).组间比较结果显示,新辅助放化疗+手术组与单纯手术组(χ2=93.346,P<0.001)和新辅助化疗+手术组(χ2=15.873,P<0.001)pCR率差异有统计学意义.多因素分析结果显示,更小的肿瘤长径(OR=4.127,95％CI:1.538～11.073,P=0.005)、无淋巴结转移(OR=21.915,95％CI:2.643～181.686,P=0.004)和新辅助放化疗(OR=0.479,95％CI:0.241～0.955,P=0.036)为pCR率的独立影响因素.结论 胸段食管鳞癌患者接受新辅助治疗后淋巴结转移率降低,同时淋巴结转移模式也有改变.肿瘤长径、淋巴结转移和新辅助放化疗与pCR相关.淋巴结清除和术后辅助治疗应结合食管癌淋巴结转移模式和pCR影响因素进行调整.

新辅助放化疗可改善患者生存,常用于晚期食管鳞癌的治疗,但部分患者无法从新辅助放化疗中获益.因此,早期准确、无创评估新辅助放化疗的疗效有重要意义.目前,评估新辅助放化疗近期疗效的方法尚未达成共识.18F-FDG PET/CT是一种无创检查方法,可评估食管鳞癌患者新辅助放化疗后肿瘤残余和远处转移情况,指导临床治疗方案的制定.本文就18 F-FDG PET/CT评估食管鳞癌新辅助放化疗近期疗效的研究进展作一综述.

Purpose: To evaluate the potential benefits of concurrent chemoradiotherapy (CCRT), and to establish a nomogram for predicting survival outcomes of elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma (SOEC). Materials and methods: This study eventually enrolled 314 elderly patients who initially diagnosed with SOEC from two centers. Treatment responses and outcomes of 151 patients receiving CCRT and 163 patients undergoing chemotherapy alone (CT) were compared. Propensity score matching and landmark analyses were performed to control potential confounding factors. A nomogram was established on the basis of the Cox regression model. Results: After a median follow-up of 42.3 months, CCRT was superior to CT alone in objective response rate (ORR, 59.6% vs. 39.9%, P < 0.001), median progression-free survival (PFS, 10.0 vs. 7.2 months, P < 0.001), and median overall survival (OS, 18.5 vs. 15.6 months, P < 0.001). The propensity score matching (PSM) and landmark analyses redemonstrated the same trend (P < 0.01). On hierarchical analysis, patients with 1- 3 metastatic lesions involving one organ displayed longer median PFS (9.0 vs. 7.8 months, P = 0.008) and OS (17.8 vs. 15.2 months, P < 0.001) than those with 4-5 metastatic lesions involving 2-3 organs. The major toxicities of grade III or higher for CCRT included leukocytopenia (23.2%), radiation esophagitis (7.3%), and radiation pneumonitis (8.6%). Cox multivariate analysis showed that the number of metastatic lesions (P = 0.012) and tumor response (P < 0.001) were independent prognostic factors associated with OS. A nomogram was established by incorporating the number of metastatic lesions and tumor response, with a concordance index of 0.743 after internal cross-validation. Calibration curves and decision curve analysis confirmed that nomogram had a favorable predictive value for individualized survival. Conclusions: Compared with CT alone, CCRT exhibited superior efficacy and acceptable toxicity in the first line treatment for elderly patients with SOEC. The current study supports the oligometastatic definition of <3 metastatic lesions involving one organ for esophageal cancer patients. The constructed nomogram can effectively predict the individualized survival. (c) 2021 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 164 (2021) 236-244

Introduction: Prednisone (10 mg/d) is often used in combination with docetaxel or abiraterone in the treatment of advanced prostate cancer. LATITUDE studies have confirmed that the combination of abiraterone and prednisone (5 mg/d) can be used for the treatment of newly diagnosed high-risk metastatic castration-sensitive prostate cancer, and have achieved satisfactory results. However, it has not been reported that abiraterone combined with prednisone (5 mg/d) in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Patient concerns: Here, we present a case of high-risk advanced prostate cancer with old pulmonary tuberculosis (PTB). The patient developed a relapse of old tuberculosis in both lungs that were discovered following 14 months of continuous application of prednisone (10 mg/d). Diagnosis: The histopathological findings showed prostate adenocarcinoma carcinoma with a Gleason score of 10 (5+5). Further laboratory investigations were suggestive of positive mycobacterium tuberculosis complex DNA in pleural effusion and sputum. Interventions: The patient underwent endocrine therapy, chemotherapy of docetaxel plus prednisone, radiotherapy, and abiraterone combined with prednisone treatment, but he eventually developed into the mCRPC stage. Then, prednisone was reduced to 5 mg/d plus abiraterone, and combined with anti-tuberculosis treatment according to multi-disciplinary diagnosis and treatment. Outcome: Two months later, pleural effusion and atelectasis were relieved, and PSA was remained stable at a low level. The patient achieved complete remission. Conclusion: We cannot, with complete certainty, say that this patient, or any patient, developed old PTB recurrence due to the use of prednisone. Based on the current evidence, endocrine therapy is the foundation, radiotherapy can reduce the tumor load, and early application of abiraterone is beneficial to survival for the high-risk mCRPC. The long-term use of prednisone can be appropriately reduced in mCRPC with old PTB, and a satisfactory curative effect can be achieved. More prospective trials are warranted before a definite recommendation could be drawn.

Background Prostate cancer (PCa) is one of the most common malignant cancer in males worldwide. Circular RNAs (CircRNAs) are novel type of non-coding RNAs. Recently, circRNAs have been reported participating in various cancers, including prostate cancer. However, the function and mechanism of circ_0057553 remain to be elucidated. Methods and Materials The RNA expression levels of circ_0057553, miR-515-5p, YES proto-oncogene 1 (YES1) and glycolytic genes mRNA were detected by qRT-PCR in PCa tissues or cells. Western blotting was performed to analyze YES1 protein level. Cell viability, migration and invasion and cell apoptosis were assessed by cell counting kit-8 (CCK-8) assay, transwell assay and flow cytometry. In addition, the effects of cell glycolysis were evaluated by measuring lactate production, glucose consumption and adenosine triphosphate (ATP) level. Moreover, dual-luciferase reporter assay was used to detect the target sites of circ_0057553 and miR-515-5p, miR-515-5p and YES1. RNA immunoprecipitation (RIP) was conducted to evaluate the target relationship between circ_0057553 and miR-515-5p. Xenograft mouse model was conducted to measure tumor formation in vivo. Results Circ_0057553 was significantly up-regulated in PCa tissues and cells. Knockdown of circ_0057553 inhibited cell viability, migration, invasion and glycolysis and facilitated apoptosis in PCa cells. Furthermore, circ_0057553 bound to miR-515-5p and miR-515-5p directly targeted YES1. Interestingly, miR-515-5p inhibitor partially rescued the function of circ_0057553 knockdown, while YES1 restored the effects of miR-515-5p overexpression. Circ_0057553 down-regulation remarkably decreased tumor volume and weight in vivo. Conclusion Circ_0057553 affected PCa cell viability, migration, invasion, apoptosis and glycolysis through miR-515-5p/YES1 axis.

Introduction Ribosome binding protein 1 (RRBP1) is reported to be correlated with tumor formation and progression. However, the role of RRBP1 in bladder cancer is unclear. In this study, we aimed to investigate the expression of RRBP1 and its influence on cell proliferation in bladder cancer. Methods Quantification real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC) were used to detect the expression levels of RRBP1 in 138 bladder cancer and matched adjacent normal bladder tissues. Then, the clinical significance of RRBP1 in bladder cancer was evaluated. The effect of RRBP1 on cell proliferation and its potential mechanism were further explored. Results Results show that the mRNA levels of RRBP1 in bladder cancer were significantly higher compared with those in normal tissues (P< 0.001). IHC results show the high-expression rate of RRBP1 in bladder cancer was 68.8%, which was significantly greater than those in normal tissues (40.6%, P< 0.001). RRBP1 high-expression was significantly associated with differentiation, T stage and lymph node metastasis in bladder cancer (P< 0.05). The overall survival time of patients with RRBP1 high-expression was significantly reduced compared to those with RRBP1 low-expression. Moreover, RRBP1 overexpression significantly promoted cell proliferation, which was correlated with Smad1/Smad3/TGF-β1 signal pathway. Conclusion RRBP1 high-expression correlates with prognosis and promotes cell proliferation in bladder cancer, which could be a potential biomarker.

目的 评估经后腹腔镜单解剖层面巨大肾上腺肿瘤切除术的手术技巧及临床效果.方法 回顾性分析笔者医院2015年1月 ～2019年12月行后腹腔镜巨大肾上腺肿瘤切除术60例患者的临床资料,单解剖层面肾上腺肿瘤切除术32例,非单解剖层面肾上腺肿瘤切除术28例.比较两组患者的手术指标及围术期的相关临床参数.结果 60例巨大肾上腺肿瘤均在后腹腔镜下完成,两组肿瘤患者的基本情况、肿瘤位置、病理类型等比较,差异均无统计学意义(P>0.05).经后腹腔镜单解剖层面肾上腺肿瘤切除术在手术时间、腹膜破损率、术中出血量及术后引流量等方面均优于非单解剖层面肾上腺肿瘤切除术,差异均有统计学意义(P<0.05).而在肿瘤完整切除率及术后恢复方面,两组比较差异无统计学意义(P>0.05).结论 经后腹腔镜单解剖层面巨大肾上腺肿瘤切除术疗效显著,值得在临床上应用推广.

目的:探讨加速康复外科(ERAS)理念对经尿道选择性绿激光前列腺汽化术(PVP)患者术后康复的安全性和有效性.方法:回顾2018年6月至2019年10月在河南科技大学第一附属医院行经尿道选择性绿激光PVP治疗的61例前列腺增生患者,其中采用加速康复理念进行围手术期管理30例(ERAS组),按照传统围手术期管理31例(对照组).比较两组手术时间、术后6h视觉模拟评分(VAS)、术后第ld血白细胞计数、术后首次排气时间、国际前列腺症状评分(IPSS)、生活质量(QOL)评分、最大尿流率(Qmax)、术后尿管留置时间、住院时间以及出院3个月内并发症发生情况等.结果:两组术后6小时VAS评分、术后排气时间、留置尿管时间、平均住院时间比较差异有统计学意义(P＜0.05).两组术后3个月IPSS评分、术后3个月QOL评分、术后3个月Qmax比较差异均无统计学意义(P＞0.05).两组术后并发症发生率比较差异无统计学意义(P＞0.05).结论:ERAS应用于经尿道选择性绿激光PVP围手术期的管理满足安全性、有效性的要求,有助于缓解术后早期疼痛感,缩短肠道恢复、住院的时间,使患者能够更快地出院和康复.

目的:探讨肾肿瘤合并肾血管变异的临床特点,以及后腹腔镜根治性肾切除术中肾血管变异的处理方法与注意事项.方法:回顾性分析2013年1月～2016年6月我院肾肿瘤患者的临床资料,统计并分析血管变异种类及特点,后腹腔镜手术中观察血管异常情况,并与具有正常血管的肾肿瘤患者手术时间、出血量和住院时间进行对比.结果:283例肾肿瘤患者中71例合并血管变异,肾血管变异患者(变异组)手术中转开放4例,肾血管正常患者(正常组)中转开放手术2例.变异组平均手术时间141 min、正常组120.6 min;变异组平均出血量178.9ml,正常组118.6 ml;两组手术时间及术中出血量比较差异有统计学意义(P＜0.05).变异组术后住院为8.2d,正常组为7.9d,两组比较差异无统计学意义(P＞0.05).结论:肾肿瘤患者血管变异率较高,血管变异增加了手术复杂性,术前明确动脉血供特点,术中仔细操作,是手术成功的关键,在夹闭肾静脉前先行阻断试验可以判断肾脏是否仍存在动脉血供,防止血管漏扎.

Objective To evaluate the clinical efficacy and safety of needleless single incision in the treatment of female stress urinary incontinence (SUI) .Methods The clinical data of 37 patients with pressure incontinence who received surgical treatment from January 2015 to January 2017 were selected, including 27 cases of pure pressure incontinence and 10 cases of mixed type. The average age was 53.1 years. The medical history was 1-20 years, with an average of 6.1 years. The follow-up time was 7-24 months, with an average of 15.3 months. All patients completed iciq-sf, iiq-7, and sex quality questionnaire before and after surgery (pisq-12) before and after surgery. The wilcoxon rank sum test was used to compare the preoperative scores. Results Thirty-seven cases completed the operation under local anethesia, 30 patients (81.1％) were cured 3 months after surgery, 6 cases (16.2％) were improved, 1 case was failed (2.7％); 29 cases (78.4％) were cured 12 months after surgery (78.4％), 7 cases were improved (19.4％), and the total effective rate was 97.3％ (2.7％), 1 case was failed. The score of IIQ-7 and iciq-sf at 3 and 12 months after operation were significantly lower than those before operation (P＜0.05) .The postoperative score of pisq-12 was increased, there was significant difference compared with the preoperative score (P＜0.05) .Conclusions Single incision needleless sling operation is simple, more minimally invasive and has fewer complications, which is an effective method for the treatment of female stress incontinence.

INTRODUCTION:Recently, increasing evidence has shown that long non-coding RNAs (lncRNAs) play critical roles in tumor progression and development. However, the expression pattern and biological function of lncRNA HULC (highly upregulated in liver cancer) in prostate cancer (PCa) remain largely unclear.MATERIAL AND METHODS:The expression of lncRNA HULC in 53 paired PCa tissues and cell lines was detected by quantitative real-time polymerase chain reaction (qRT-PCR). The χ2 test was used to explore the association of lncRNA HULC expression with clinicopathologic features. Kaplan-Meier analysis was used to detect the association between HULC expression and overall survival of PCa patients. Furthermore, the function of HULC in cell growth and metastasis was detected in PCa cells.RESULTS:Our data showed that HULC expression was upregulated in PCa tissues and cell lines compared to adjacent non-tumor tissues and the normal prostate cell line RWPE-1 (p < 0.05). High HULC expression was positively associated with advanced clinicopathologic features and poor overall survival (OS) for PCa patients (p < 0.05). HULC inhibition suppressed PCa cell growth and metastasis both in vitro and in vivo (p < 0.05). Furthermore, HULC knockdown reduced N-cadherin and vimentin expression and increased E-cadherin expression in PCa cells (p < 0.05).CONCLUSIONS:Our data suggested that lncRNA HULC might play oncogenic roles in PCa progression, which provided a novel therapeutic strategy for PCa patients.

Increasing evidence showed that circular RNAs (circRNAs) play critical roles in tumorigenesis. However, the roles and underlying mechanisms of circRNAs in clear cell renal cell carcinoma (ccRCC) remain unclear. In the present study, we identified a novel circRNA circPCNXL2, which was significantly upregulated in ccRCC by circular RNA microarray. Further analysis revealed that circPCNXL2 was significantly increased and correlated with poor overall survival of ccRCC patients. Function assays revealed that circPCNXL2 knockdown reduced RCC cells proliferation, invasion in vitro, and decreased tumor growth in vivo. In mechanism study, we showed that circPCNXL2 could be bind to miR-153 as a miRNA sponge to regulate ZEB2 expression in RCC progression. In addition, our data reported that the effects of circPCNXL2 inhibition on RCC cells proliferation and invasion could be abolished by miR-153 inhibitors. Altogether, we demonstrated that circPCNXL2 could regulate RCC cells proliferation and invasion by miR-153/ZEB2 axis, suggesting circPCNXL2 might serve as a potential therapeutic target for ccRCC treatment.

Objective To evaluate the safety and efficacy of retroperitoneal laparoscopic procedure for rad-ical nephrectomy. Methods The clinical data of 140 cases underwent retroperitoneal aparoscopic radical nephrec-tomy from August 2013 to December 2015 were retrospectively analyzed. Among them ,87 cases were controlled by procedure for radical nephrectomy ,53 cases were treated with Non-procedural for radical nephrectomy. The peri-operative information parameters of the two groups were compared and analyzed. Results All of the 140 cases were operated under laparoscopy. There was no significant difference between the two groups in the basic condition and tumor location(P>0.05). Retroperitoneal laparoscopic procedure in the operation time ,intraoperative bleed-ing,peritoneal rupture rate,blood transfusion,complete tumor resection and postoperative drainage were better than non-procedural for radical nephrectomy ,the differences were statistically significant(P<0.01). All patients were followed up for 1 to 3 years without recurrence and metastasis. Conclusion Retroperitoneal laparoscopic pro-cedure for radical nephrectomy is significant ,worthy of clinical application and promotion.